-

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Atlassian Corporation (TEAM)

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all purchasers of Atlassian Corporation (NASDAQ: TEAM) ordinary shares and/or common stock between August 5, 2022 and November 3, 2022, for violations of the Securities Act of 1934. Atlassian develops and sells collaboration and project-management software that operates both on premises and in the cloud.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Atlassian. Shareholders who want to act as lead plaintiff for the class must file their papers by April 4, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: Atlassian Corporation (TEAM) Misled Investors Regarding the Company's Financial Viability and Business Prospects

According to the complaint, leading up to the class period, defendants touted the Company's financial viability. After markets closed on August 4, 2022, defendant Co-Chief Executive Officer Scott Farquhar reiterated the Company’s guidance of 50% year-on-year cloud growth for fiscal years 2023 and 2024. In a call with analysts that day, defendant and Chief Revenue Officer Cameron Deatsch assured investors the Company was “being exceedingly vigilant watching all stages of our funnel” and that “we have yet to see any specific trend . . . that gives us pause or worry to date.” According to CRO Deatsch, the “demand for collaboration products continue[s] to be strong.”

In reality, Atlassian overstated its financial guidance by concealing trends of slowing conversions from free users to paying customers and slowing growth in paying-user expansion. As a result, defendants’ positive statements about the Company’s business, operations, and prospects during the class period were materially false and/or misleading.

On November 3, 2022, Atlassian issued a letter to shareholders and held a conference call with analysts to discuss its financial results for the fiscal first quarter of 2023 ended September 30, 2022. In the letter to shareholders, defendants revealed that “[b]ased on the macro headwinds,” the Company was “lowering our Cloud revenue growth outlook to a range of approximately 40% to 45% year-over-year” for fiscal year 2023. In describing the “macro impacts” on the Company, the letter to shareholders revealed that (1) the Company “saw a decrease in the rate of Free instances converting to paid plans,” calling it a “trend [that] became more pronounced” in the quarter and (2) the Company experienced “a slowing in the rate of paid user growth from existing customers.” In response to these revelations, the price of Atlassian stock declined almost 29% the following trading day, from a closing price of $174.17 per share on November 3, 2022 to a closing price of $123.73 per share on November 4, 2022. More than $7 billion in shareholder value evaporated. Analysts reported being “surprised by the magnitude of the slowdown” as defendants “delivered unusually disappointing” results.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Atlassian Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:TEAM

Release Summary
Atlassian Corporation (TEAM) Misled Investors Regarding the Company's Financial Viability and Business Prospects
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

CPNG Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Coupang, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coupang, Inc. (NYSE: CPNG) securities between April 6, 2025 and December 16, 2025. Coupang describes itself as one of the fastest-growing technology and commerce companies in the world, providing retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Cou...

Did You Lose Money in SFM? Stockholders Who Incurred Significant Financial Loss in Sprouts Farmers Market, Inc. Should Contact Robbins LLP to Learn About Leading the SFM Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Sprouts Farmers Market, Inc. (NASDAQ: SFM) is a specialty grocery store chain that operates in the U.S. What is the class period? June 4, 2025 - October 29, 2025. What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Sprouts Farmers Market, Inc. during the class period because the Company allegedly misled investors regarding its growth potential. For...

MCTA Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Class Action Against Charming Medical, Limited

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025. The Company claims to “enhance[] the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology.” For more information, submit a form, email attorney Aaron Dumas, Jr., or give...
Back to Newsroom